Cargando…

PTH Assays: Understanding What We Have and Forecasting What We Will Have

Parathyroid hormone (PTH) assays have evolved continuously for the last 50 years. Since the first radioimmunoassay was described in 1963, several assays based on immunological identification have been published (first generation assays). The routine assays used nowadays are immunometric “sandwich-ty...

Descripción completa

Detalles Bibliográficos
Autor principal: Vieira, Jose Gilberto H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324155/
https://www.ncbi.nlm.nih.gov/pubmed/22548199
http://dx.doi.org/10.1155/2012/523246
_version_ 1782229286208405504
author Vieira, Jose Gilberto H.
author_facet Vieira, Jose Gilberto H.
author_sort Vieira, Jose Gilberto H.
collection PubMed
description Parathyroid hormone (PTH) assays have evolved continuously for the last 50 years. Since the first radioimmunoassay was described in 1963, several assays based on immunological identification have been published (first generation assays). The routine assays used nowadays are immunometric “sandwich-type”. They are based on two different monoclonal antibodies, one amino-terminal and the other carboxyl terminal specific. These second generation assays are widely available and adapted to most of the automation platforms. The specificity of the amino terminal antibody defines if the immunometric assay measures only the bioactive PTH circulating form (including the first amino terminal amino acids) or the “intact” PTH, which includes, besides bioactive PTH, other “long” carboxyl-terminal forms, for example, 7–84-PTH. Assays for “intact” PTH are the most commonly available and the potential advantage of the bioactive PTH assays is still debatable. Next generation of assays will be based on different principles, mainly mass spectrometry in samples submitted to a prior purification and fragmentation steps. These assays will provide information about the whole spectra of PTH peptides in circulation, with a significant increase of the information regarding this biologically important peptide hormone.
format Online
Article
Text
id pubmed-3324155
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33241552012-04-30 PTH Assays: Understanding What We Have and Forecasting What We Will Have Vieira, Jose Gilberto H. J Osteoporos Review Article Parathyroid hormone (PTH) assays have evolved continuously for the last 50 years. Since the first radioimmunoassay was described in 1963, several assays based on immunological identification have been published (first generation assays). The routine assays used nowadays are immunometric “sandwich-type”. They are based on two different monoclonal antibodies, one amino-terminal and the other carboxyl terminal specific. These second generation assays are widely available and adapted to most of the automation platforms. The specificity of the amino terminal antibody defines if the immunometric assay measures only the bioactive PTH circulating form (including the first amino terminal amino acids) or the “intact” PTH, which includes, besides bioactive PTH, other “long” carboxyl-terminal forms, for example, 7–84-PTH. Assays for “intact” PTH are the most commonly available and the potential advantage of the bioactive PTH assays is still debatable. Next generation of assays will be based on different principles, mainly mass spectrometry in samples submitted to a prior purification and fragmentation steps. These assays will provide information about the whole spectra of PTH peptides in circulation, with a significant increase of the information regarding this biologically important peptide hormone. Hindawi Publishing Corporation 2012 2012-04-03 /pmc/articles/PMC3324155/ /pubmed/22548199 http://dx.doi.org/10.1155/2012/523246 Text en Copyright © 2012 Jose Gilberto H. Vieira. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Vieira, Jose Gilberto H.
PTH Assays: Understanding What We Have and Forecasting What We Will Have
title PTH Assays: Understanding What We Have and Forecasting What We Will Have
title_full PTH Assays: Understanding What We Have and Forecasting What We Will Have
title_fullStr PTH Assays: Understanding What We Have and Forecasting What We Will Have
title_full_unstemmed PTH Assays: Understanding What We Have and Forecasting What We Will Have
title_short PTH Assays: Understanding What We Have and Forecasting What We Will Have
title_sort pth assays: understanding what we have and forecasting what we will have
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324155/
https://www.ncbi.nlm.nih.gov/pubmed/22548199
http://dx.doi.org/10.1155/2012/523246
work_keys_str_mv AT vieirajosegilbertoh pthassaysunderstandingwhatwehaveandforecastingwhatwewillhave